Opioid use disorder Cascade of care framework design: A roadmap

References

• Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):1207–207.
   Google Scholar
• Ahmad LB, Rossen LM, Sutton P. Provisional Drug Overdose Death Counts. Hyattsville: National Center for Health Statistics; 2021.
   Google Scholar
• 2019 National Survey of Drug Use and Health (NSDUH) Releases | CBHSQ Data. https://www.samhsa.gov/data/release/2019-national-survey-drug-use-and-health-nsduh-releases. Accessed October 2021.
   Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Bmj. 2017;357:j1550–14.
   PubMed Web of Science ®Google Scholar
• Santo T, Jr., Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979–993.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine (NASEM). Medications for Opioid Use Disorders save Lives. Washington, DC: The National Academies Press; 2019.
   Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
   PubMed Web of Science ®Google Scholar
• SAMHSA Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2015. Data on Substance Abuse Treatment Facilities. BHSIS Series S-88, HHS Publication No. (SMA) 17-5031. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
   Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145.
   PubMed Web of Science ®Google Scholar
• Samples H, Williams AR, Olfson M, Crystal S. Risk factors for premature discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of medicaid enrollees. J Subst Abus Treat. 2018;95:9–17.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2012;21(1):55–62.
   PubMed Web of Science ®Google Scholar
• Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015;52:48–57.
   PubMed Web of Science ®Google Scholar
• Socías ME, Volkow N, Wood E. Adopting the ‘cascade of care’ framework: an opportunity to close the implementation gap in addiction care? Addiction. 2016;111(12):2079–2081.
   PubMed Web of Science ®Google Scholar
• Knight DK, Belenko S, Wiley T, et al. Juvenile Justice-Translational Research on Interventions for Adolescents in the Legal System (JJ-TRIALS): a cluster randomized trial targeting system-wide improvement in substance use services. Implement Sci. 2016;11(1):57.
   PubMedGoogle Scholar
• Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a Cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1–10.
   PubMed Web of Science ®Google Scholar
• Williams AR, Nunes EV, Bisaga A, et al. Developing an opioid use disorder treatment Cascade: a review of quality measures. J Subst Abus Treat. 2018;91:57–68.
   PubMed Web of Science ®Google Scholar
• Johnson K, Williams AR, Chalk M. Making the opioid use disorder cascade of care a reality, despite data limitations. Health Affairs Blog. 2018.
   Google Scholar
• Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. The Lancet. 2019;393(10182):1760–1772.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus. 2020;41(3):275–281.
   PubMed Web of Science ®Google Scholar
• Bipartisan Policy Center. Tracking Federal Funding to Combat the Opioid Crisis, 2019: p. 61.
   Google Scholar
• Williams AR, Olfson M, Nunes EV. To battle the opioid epidemic, deploy the ‘Cascade of Care’ model. Health Affairs, Health Policy Lab. 2017.
   Google Scholar
• McCorry F, Garnick DW, Bartlett J, Cotter F, Chalk M. Developing performance measures for alcohol and other drug services in managed care plans. Washington Circle Group. Jt Comm J Qual Improv. 2000;26(11):633–643.
   PubMedGoogle Scholar
• HEDIS® Technical Specifications for Health Plans Vol. 2. Washington, CA: National Committee for Quality Assurance; 2018. http://store.ncqa.org/index.php/catalog/product/view/id/2871/s/hedis-2018-volume-2-epub/. Accessed August 16, 2019.
   Google Scholar
• NQF core measure set for Mcaid: https://www.medicaid.gov/medicaid/quality-of-care/downloads/2021-bh-core-set.pdf
   Google Scholar
• National Quality Forum. Opioids and opioid use disorder: an environmental scan of quality measures; Final Report September 12, 2019; https://www.qualityforum.org/Publications/2019/09/Opioid_and_Opioid_Use_Disorder_Final_Environmental_Scan.aspx; Accessed October, 2021.
   Google Scholar
• Jamieson D, Kellerman SE. The 90-90-90 strategy to end the HIV Pandemic by 2030: can the supply chain handle it? J Int AIDS Soc. 2016;19(1):20917.
   PubMed Web of Science ®Google Scholar
• Farnham P, Chen YH, Gopalappa C. Vital signs: HIV transmission along the continuum of care—United States, 2016. https://stacks.cdc.gov/view/cdc/76585. Accessed July 5, 2019.
   Google Scholar
• Dematteis M, Auriacombe M, D'Agnone O, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;18(18):1987–1999.
   PubMed Web of Science ®Google Scholar
• Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–367.
   PubMed Web of Science ®Google Scholar
• Johnson K, Hills H, Ma J, Brown CH, McGovern M. Treatment for opioid use disorder in the Florida medicaid population: using a cascade of care model to evaluate quality. Am J Drug Alcohol Abuse. 2021;47(2):220–229.
   PubMed Web of Science ®Google Scholar
• Yedinak JL, Goedel WC, Paull K, et al. Defining a recovery-oriented cascade of care for opioid use disorder: a community-driven, statewide cross-sectional assessment. PLoS Med. 2019;16(11):e1002963.
   PubMed Web of Science ®Google Scholar
• Prieto JT, McEwen D, Davidson AJ, et al. Monitoring opioid addiction and treatment: do you know if your population is engaged? Drug Alcohol Depend. 2019;202:56–60.
   PubMed Web of Science ®Google Scholar
• Socías ME, Wood E, Kerr T, et al. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006–2016. Drug and Alc Depend. 2018;189:90–95.
   PubMed Web of Science ®Google Scholar
• Piske M, Zhou H, Min JE, et al. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction. 2020;115(8):1482–1493.
   PubMed Web of Science ®Google Scholar
• National Quality Forum. #3175 Continuity of Pharmacotherapy for Opioid Use Disorder. NQF 2018.
   Google Scholar
• Haber N, Pillay D, Porter K, Barnighausen T. Constructing the cascade of HIV care: methods for measurement. Curr Opin HIV Aids. 2016;11(1):102–108.
   PubMed Web of Science ®Google Scholar
• Krebs E, Min JE, Zhou H, Davison C, McGowan G, Nosyk B. The cascade of care for opioid use disorder among youth in British Columbia, 2018. J Subst Abuse Treat. 2021;130:108404.
   PubMedGoogle Scholar
• Gonsalves GS, Paltiel AD, Cleary PD, et al. A flow-based model of the HIV care continuum in the United States. J Acquir Immune Defic Syndr. 2017;75(5):548–553.
   PubMed Web of Science ®Google Scholar
• Donohue JM, Jarlenski MP, Kim JY, et al. Use of medications for treatment of opioid use disorder among US Medicaid Enrollees in 11 States, 2014–2018. JAMA. 2021;326(2):154–164.
   PubMedGoogle Scholar
• Belenko S, Knight D, Wasserman GA, et al. Sales J, The Juvenile Justice Behavioral Health Services Cascade: a new framework for measuring unmet substance use treatment services needs among adolescent offenders. J Subst Abuse Treat. 2017;74:80–91.
   PubMed Web of Science ®Google Scholar
• Scott CK, Dennis ML, Grella CE, et al. A community outreach intervention to link individuals with opioid use disorders to medication-assisted treatment. J Subst Abuse Treat. 2020;108:75–81.
   PubMed Web of Science ®Google Scholar
• Upadhyaya A, Marks LR, Schwarz ES, Liang SY, Durkin MJ, Liss DB. Care cascade for patients with opioid use disorder and serious injection related infections. Toxicol Commun. 2021;5(1):6–10.
   PubMedGoogle Scholar
• Boyd T, Stipek J, Kraft A, et al. Quantifying opioid use disorder Cascade of Care outcomes in an American Indian tribal nation in Minnesota. Drug Alcohol Depend. 2021;222:108661.
   PubMedGoogle Scholar
• Tiako MJN, Friedman A, Culhane J, South E, Meisel ZF. Predictors of initiation of medication for opioid use disorder and retention in treatment among U.S. Pregnant Women, 2013–2017. Obstet Gynecol. 2021;137(4):687–694.
   PubMedGoogle Scholar